Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.51 |
| ▸ | HRH4 | Q9H3N8 | 10/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.47 |
| ▸ | HTR6 | P50406 | 1/20 | 0.46 |
| ▸ | ADCY10 | Q96PN6 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL602379 | 1.00 | HSP90AB1 (0.51) | HSP90AB1HRH4HRH3HTR6ADCY10 | |
| SCHEMBL605777 | 0.85 | HSP90AB1 (0.51) | HSP90AB1HRH4HRH3HTR6 | |
| SCHEMBL605778 | 0.85 | HSP90AB1 (0.51) | HSP90AB1HRH4HRH3HTR6 | |
| SCHEMBL605761 | 0.84 | HRH4 (0.67) | HSP90AB1HRH4HRH3HTR6 | |
| SCHEMBL14114525 | 0.79 | HSP90AB1 (0.59) | HSP90AB1HRH4HTR6 | |
| SCHEMBL602381 | 0.78 | HRH4 (0.47) | HSP90AB1HRH4HRH3HTR6ADCY10 | |
| SCHEMBL606496 | 0.78 | HRH4 (0.60) | HRH4HRH3 | |
| SCHEMBL606495 | 0.78 | HRH4 (0.60) | HRH4HRH3 | |
| SCHEMBL603018 | 0.78 | HRH4 (0.82) | HSP90AB1HRH4HRH3 | |
| SCHEMBL603017 | 0.78 | HRH4 (0.82) | HSP90AB1HRH4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2599386-A1 | 2-aminopyrimidine modulators of the histamine h4 receptor | Janssen Pharmaceutica N.V. (BE) | 2013-06-05 | — | — | EP | claimed |
| US-20110218338-A1 | 2-AMINOPYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | Janseen Pharmaceutiacal NV | 2011-09-08 | — | — | US | claimed |
| US-20080194577-A1 | Antiallergens; asthma; autoimmune disease; pruritius; antiarthritic agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-08-14 | — | — | US | claimed |
| US-10195195-B2 | Selective histamine H4 receptor antagonists for the treatment of vestibular disorders | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2019-02-05 | — | — | US | disclosed |
| EP-3378476-A1 | H4 RECEPTOR INHIBITORS FOR TREATING TINNITUS | Sensorion (FR) | 2018-09-26 | — | — | EP | disclosed |
| US-9688989-B2 | H4 receptor inhibitors for treating tinnitus | SENSORION (FR) | 2017-06-27 | — | — | US | disclosed |
| US-20170056397-A1 | SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2017-03-02 | — | — | US | disclosed |
| US-9526725-B2 | Selective histamine H4 receptor antagonists for the treatment of vestibular disorders | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2016-12-27 | — | — | US | disclosed |
| US-20150176010-A1 | H4 RECEPTOR INHIBITORS FOR TREATING TINNITUS | SENSORION (FR) | 2015-06-25 | — | — | US | disclosed |
| EP-2858647-A1 | H4 RECEPTOR INHIBITORS FOR TREATING TINNITUS | Sensorion (FR) | 2015-04-15 | — | — | EP | disclosed |
| US-8716475-B2 | 2-aminopyrimidine modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2014-05-06 | — | — | US | disclosed |
| US-20110160451-A1 | 2-Aminopyrimidine modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA NV | 2011-06-30 | — | — | US | disclosed |
| US-7923451-B2 | Antiallergens; asthma; autoimmune disease; pruritius; antiarthritic agents | JANSSEN PHARMACEUTICA NV (BE) | 2011-04-12 | — | — | US | disclosed |
| US-7923451-B2 | Antiallergens; asthma; autoimmune disease; pruritius; antiarthritic agents | JANSSEN PHARMACEUTICA NV (BE) | 2011-04-12 | — | — | US | disclosed |
| US-7923451-B2 | Antiallergens; asthma; autoimmune disease; pruritius; antiarthritic agents | JANSSEN PHARMACEUTICA NV (BE) | 2011-04-12 | — | — | US | disclosed |
| WO-2010072829-A1 | SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS. | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2010-07-01 | — | — | WO | disclosed |
| WO-2008100565-A1 | 2-AMINOPYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-08-21 | — | — | WO | disclosed |
| US-20080194577-A1 | Antiallergens; asthma; autoimmune disease; pruritius; antiarthritic agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-08-14 | — | — | US | disclosed |
| US-20080194577-A1 | Antiallergens; asthma; autoimmune disease; pruritius; antiarthritic agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-08-14 | — | — | US | disclosed |
| US-20080194577-A1 | Antiallergens; asthma; autoimmune disease; pruritius; antiarthritic agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160451-A1 | 2-Aminopyrimidine modulators of the histamine H4 receptor | HRH4, HRH2, HRH3 | HSP90AB1 2392/4885HRH4 1/4885HRH3 3/4885 |
| US-20110218338-A1 | 2-AMINOPYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | HRH4, HRH2, HRH3 | HSP90AB1 2376/4885HRH4 1/4885HRH3 3/4885 |
| US-20080194577-A1 | Antiallergens; asthma; autoimmune disease; pruritius; antiarthritic agents | HRH4, HRH2, HRH3 | HSP90AB1 2124/4885HRH4 1/4885HRH3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.